LQDA

Liquidia Corporation · NASDAQ

Performance

-1.34%

1W

-13.92%

1M

+3.1%

3M

+19.3%

6M

+13.01%

YTD

+0.83%

1Y

Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Technical Analysis of LQDA 2025-04-21

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 25 indicating strong downward pressure, while the Technical Score of 37 further supports this outlook. The Oscillators Score of 50 suggests a neutral stance, but overall, the combined scores indicate a lack of bullish momentum in the market.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of LQDA

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.